Agios Pharmaceuticals AGIO Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's share-based payment award options outstanding - number?
- Agios Pharmaceuticals (AGIO) reported share-based payment award options outstanding - number of 6.6M in Q1 2026.
- How has Agios Pharmaceuticals's share-based payment award options outstanding - number changed year-over-year?
- Agios Pharmaceuticals's share-based payment award options outstanding - number increased by 4.2% year-over-year, from 6.4M to 6.6M.
- What is the long-term trend for Agios Pharmaceuticals's share-based payment award options outstanding - number?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's share-based payment award options outstanding - number has grown at a -0.1% compound annual growth rate (CAGR), from 6.1M to 6.1M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.